Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST)

Francesco Bertagna; Giovanni Bosio; Emanuela Orlando; Giorgio Biasiotto; Raffaele Giubbini

Vol 13, No 2 (2010)

Research paper

Submitted: 2012-01-23

Published online: 2011-05-20

View PDF

Download PDF file

Get Citation

Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST)

Francesco Bertagna, Giovanni Bosio, Emanuela Orlando, Giorgio Biasiotto, Raffaele Giubbini

Nucl. Med. Rev 2010;13(2):76-80.

Vol 13, No 2 (2010)

Original articles

Submitted: 2012-01-23

Published online: 2011-05-20

Abstract

BACKGROUND: Gastrointestinal stromal tumours (GISTs) are a subset of mesenchymal tumours that represent the most common mesenchymal neoplasms of the gastrointestinal (GI) tract and account for less than 1% of all gastrointestinal tumours.
MATERIAL AND METHODS: We retrospectively evaluated 19 patients (6 females and 13 males; median age: 61 years ± 15 standard deviation) affected by GIST histologically documented after surgical intervention or biopsy.
RESULTS: F18-FDG-PET/CT had identified pathologic uptakes and was considered positive for neoplastic tissue in 10 patients (53%) and negative in 9 (47%), in concordance with radiological findings.
CONCLUSIONS: F18-FDG-PET/CT is a feasible, reliable, and accurate method to restage patients affected by previously histologically confirmed GIST, also in the absence of a staging study.
Nuclear Med Rev 2010; 13, 2: 76–80